Closing Announcement of FY2021
CONSOLEIDATED STATEMENTS OF FINANCIAL POSITION
As of December 31, 2021
(Unit : KRW)
| Account | Amount | Account | Amount |
|---|---|---|---|
| ASSETS | LIABILITIES | ||
| 1. CURRENT ASSETS | 2,823,175,325,351 | 1. CURRENT LIABILITIES | 1,107,294,649,465 |
| Cash and cash equivalents | 47,410,383,773 | Trade and other current payables | 399,030,093,590 |
| Short-term financial instruments | 450,000,000,000 | Emission liability | 725,692,500 |
| Financial assets at fair value through profit or | 850,039,876,800 | Debentures and borrowings | 159,855,000,000 |
| Trade and other current receivables | 366,330,684,127 | Other current liabilities | 364,409,220,047 |
| Inventories | 1,012,870,791,066 | Contract liabilities | 65,563,229,062 |
| Other current financial assets | 23,984,945,243 | Lease liabilities | 7,537,132,303 |
| Other current assets | 8,627,800,354 | Current tax liabilities | 110,174,301,963 |
| Current contract assets | 63,910,843,988 | ||
| Ⅱ. NON-CURRENT LIABILITIES | 1,871,613,996,718 | ||
| Trade and other payables | 9,152,703,103 | ||
| Debentures and borrowings | 1,114,683,996,094 | ||
| Other non-current liabilities | 29,335,889,118 | ||
| Contract liabilities | 220,058,599,452 | ||
| Ⅱ. NON-CURRENT ASSETS | 5,146,835,461,512 | Deferred tax liabilities | 487,711,642,843 |
| Long-term financial instruments | 189,491,294 | ||
| Investments in associate and joint venture | 2,661,309,486,003 | TOTAL LIABILITIES | 2,978,908,646,183 |
| Property, pant and equipment | 2,207,063,705,617 | ||
| Intangible assets | 32,171,618,395 | EQUITY | |
| Right-of-use assets | 20,623,773,334 | Share capital | 165,412,500,000 |
| Trade andother receivables | 4,428,344,378 | Share premium | 2,487,313,082,024 |
| Defined beneift asset | 3,572,380,111 | Accumulated other comprehensive loss | (8,810,638,260) |
| Other non-current financial assets | 26,919,379,491 | Retained earnings | 2,347,187,196,916 |
| Other non-current assets | 1,226,182,746 | ||
| Contract assets | 189,331,100,143 | TOTAL EQUITY | 4,991,102,140,680 |
| TOTAL ASSETS | 7,970,010,786,863 | TOTAL LIABILITIES AND EQUITY | 7,970,010,786,863 |
March 29, 2022
SAMSUNG BIOLOGICS CO., LTD
president & CEO John Rim
The financial statements present fairly, in all material respects, the financial position the Company as of December 31, 2021
Samil PricewaterhouseCoopers CEO Soonsoo Yoon
Closing Announcement of FY2021
SEPARATE STATEMENTS OF FINANCIAL POSITION
As of December 31, 2021
(Unit : KRW)
| Account | Amount | Account | Amount |
|---|---|---|---|
| ASSETS | LIABILITIES | ||
| 1. CURRENT ASSETS | 2,814,680,165,198 | 1. CURRENT LIABILITIES | 1,106,401,003,784 |
| Cash and cash equivalents | 39,169,916,298 | Trade and other current payables | 398,800,894,639 |
| Short-term financial instruments | 450,000,000,000 | Emission liability | 725,692,500 |
| Financial assets at fair value through profit or loss | 850,039,876,800 | Debentures and borrowings | 159,855,000,000 |
| Trade and other receivables | 366,337,715,553 | Other current liabilities | 364,409,220,047 |
| Inventories | 1,012,870,791,066 | Contract liabilities | 65,563,229,062 |
| Other current financial assets | 23,984,945,243 | Lease liabilities | 6,834,654,592 |
| Other current assets | 8,366,076,250 | Current tax liabilities | 110,212,332,944 |
| Current contract assets | 63,910,843,988 | ||
| Ⅱ. NON-CURRENT LIABILITIES | 1,381,738,894,488 | ||
| Trade and other payables | 9,152,703,103 | ||
| Debentures and borrowings | 1,114,683,996,094 | ||
| Other non-current liabilities | 29,335,889,118 | ||
| Ⅱ. NON-CURRENT ASSETS | 3,088,731,543,731 | Contract liabilities | 220,058,599,452 |
| Long-term financial instruments | 7,000,000 | Lease liabilities | 8,507,706,721 |
| Investments in subsiduary, associate and joint | 541,389,156,596 | ||
| Property, pant and equipment | 2,202,972,181,287 | TOTAL LIABILITIES | 2,488,139,898,272 |
| Intangible assets | 32,152,176,195 | ||
| Right-of-use assets | 17,883,815,006 | EQUITY | |
| Trade andother receivables | 4,428,344,378 | Share capital | 165,412,500,000 |
| Defined beneift asset | 3,572,380,111 | Share premium | 2,496,626,850,551 |
| Other non-current financial assets | 26,919,379,491 | Accumulated other comprehensive loss | (12,943,779,648) |
| Other non-current assets | 1,226,182,746 | Retained earnings | 766,176,239,754 |
| Contract assets | 189,331,100,143 | ||
| Deferred tax assets | 68,849,827,778 | TOTAL EQUITY | 3,415,271,810,657 |
| TOTAL ASSETS | 5,903,411,708,929 | TOTAL LIABILITIES AND EQUITY | 5,903,411,708,929 |
March 29, 2022
SAMSUNG BIOLOGICS CO., LTD
president & CEO John Rim
The financial statements present fairly, in all material respects, the financial position the Company as of December 31, 2021 and its financial performance and its cash flows for the years ended December 31, 2020 in accordance with K-IFRS.
Samil PricewaterhouseCoopers CEO Soonsoo Yoon
Closing Announcement of FY2021
CONSOLEIDATED STATEMENTS OF FINANCIAL POSITION
As of December 31, 2021
(Unit : KRW)
| Account | Amount | Account | Amount |
|---|---|---|---|
| ASSETS | LIABILITIES | ||
| 1. CURRENT ASSETS | 2,823,175,325,351 | 1. CURRENT LIABILITIES | 1,107,294,649,465 |
| Cash and cash equivalents | 47,410,383,773 | Trade and other current payables | 399,030,093,590 |
| Short-term financial instruments | 450,000,000,000 | Emission liability | 725,692,500 |
| Financial assets at fair value through profit or | 850,039,876,800 | Debentures and borrowings | 159,855,000,000 |
| Trade and other current receivables | 366,330,684,127 | Other current liabilities | 364,409,220,047 |
| Inventories | 1,012,870,791,066 | Contract liabilities | 65,563,229,062 |
| Other current financial assets | 23,984,945,243 | Lease liabilities | 7,537,132,303 |
| Other current assets | 8,627,800,354 | Current tax liabilities | 110,174,301,963 |
| Current contract assets | 63,910,843,988 | ||
| Ⅱ. NON-CURRENT LIABILITIES | 1,871,613,996,718 | ||
| Trade and other payables | 9,152,703,103 | ||
| Debentures and borrowings | 1,114,683,996,094 | ||
| Other non-current liabilities | 29,335,889,118 | ||
| Contract liabilities | 220,058,599,452 | ||
| Ⅱ. NON-CURRENT ASSETS | 5,146,835,461,512 | Deferred tax liabilities | 487,711,642,843 |
| Long-term financial instruments | 189,491,294 | ||
| Investments in associate and joint venture | 2,661,309,486,003 | TOTAL LIABILITIES | 2,978,908,646,183 |
| Property, pant and equipment | 2,207,063,705,617 | ||
| Intangible assets | 32,171,618,395 | EQUITY | |
| Right-of-use assets | 20,623,773,334 | Share capital | 165,412,500,000 |
| Trade andother receivables | 4,428,344,378 | Share premium | 2,487,313,082,024 |
| Defined beneift asset | 3,572,380,111 | Accumulated other comprehensive loss | (8,810,638,260) |
| Other non-current financial assets | 26,919,379,491 | Retained earnings | 2,347,187,196,916 |
| Other non-current assets | 1,226,182,746 | ||
| Contract assets | 189,331,100,143 | TOTAL EQUITY | 4,991,102,140,680 |
| TOTAL ASSETS | 7,970,010,786,863 | TOTAL LIABILITIES AND EQUITY | 7,970,010,786,863 |
March 29, 2022
SAMSUNG BIOLOGICS CO., LTD
president & CEO John Rim
The financial statements present fairly, in all material respects, the financial position the Company as of December 31, 2021
Samil PricewaterhouseCoopers CEO Soonsoo Yoon
Closing Announcement of FY2021
SEPARATE STATEMENTS OF FINANCIAL POSITION
As of December 31, 2021
(Unit : KRW)
| Account | Amount | Account | Amount |
|---|---|---|---|
| ASSETS | LIABILITIES | ||
| 1. CURRENT ASSETS | 2,814,680,165,198 | 1. CURRENT LIABILITIES | 1,106,401,003,784 |
| Cash and cash equivalents | 39,169,916,298 | Trade and other current payables | 398,800,894,639 |
| Short-term financial instruments | 450,000,000,000 | Emission liability | 725,692,500 |
| Financial assets at fair value through profit or loss | 850,039,876,800 | Debentures and borrowings | 159,855,000,000 |
| Trade and other receivables | 366,337,715,553 | Other current liabilities | 364,409,220,047 |
| Inventories | 1,012,870,791,066 | Contract liabilities | 65,563,229,062 |
| Other current financial assets | 23,984,945,243 | Lease liabilities | 6,834,654,592 |
| Other current assets | 8,366,076,250 | Current tax liabilities | 110,212,332,944 |
| Current contract assets | 63,910,843,988 | ||
| Ⅱ. NON-CURRENT LIABILITIES | 1,381,738,894,488 | ||
| Trade and other payables | 9,152,703,103 | ||
| Debentures and borrowings | 1,114,683,996,094 | ||
| Other non-current liabilities | 29,335,889,118 | ||
| Ⅱ. NON-CURRENT ASSETS | 3,088,731,543,731 | Contract liabilities | 220,058,599,452 |
| Long-term financial instruments | 7,000,000 | Lease liabilities | 8,507,706,721 |
| Investments in subsiduary, associate and joint | 541,389,156,596 | ||
| Property, pant and equipment | 2,202,972,181,287 | TOTAL LIABILITIES | 2,488,139,898,272 |
| Intangible assets | 32,152,176,195 | ||
| Right-of-use assets | 17,883,815,006 | EQUITY | |
| Trade andother receivables | 4,428,344,378 | Share capital | 165,412,500,000 |
| Defined beneift asset | 3,572,380,111 | Share premium | 2,496,626,850,551 |
| Other non-current financial assets | 26,919,379,491 | Accumulated other comprehensive loss | (12,943,779,648) |
| Other non-current assets | 1,226,182,746 | Retained earnings | 766,176,239,754 |
| Contract assets | 189,331,100,143 | ||
| Deferred tax assets | 68,849,827,778 | TOTAL EQUITY | 3,415,271,810,657 |
| TOTAL ASSETS | 5,903,411,708,929 | TOTAL LIABILITIES AND EQUITY | 5,903,411,708,929 |
March 29, 2022
SAMSUNG BIOLOGICS CO., LTD
president & CEO John Rim
The financial statements present fairly, in all material respects, the financial position the Company as of December 31, 2021 and its financial performance and its cash flows for the years ended December 31, 2020 in accordance with K-IFRS.
Samil PricewaterhouseCoopers CEO Soonsoo Yoon
- CDO
- CGMP
- ADC
- Bio Campus
- IR
- CMO